subscribeSubscribe
FDA Roundup: August 20, 2024

FDA Roundup: August 20, 2024
PR NEWSWIRE
20 Aug 2024
Share Share
PALOMA-2: Amivantamab/Lazertinib Shows Response, Safety In EGFR+ NSCLC

PALOMA-2: Amivantamab/Lazertinib Shows Response, Safety In EGFR+ NSCLC
PR NEWSWIRE
03 Jun 2024
Share Share
PALOMA-2: Subcutaneous RYBREVANT Combo Shows Response, Safety In EGFR+ NSCLC

PALOMA-2: Subcutaneous RYBREVANT Combo Shows Response, Safety In EGFR+ NSCLC
GLOBENEWSWIRE
03 Jun 2024
Share Share
PALOMA-3: 5-Min Subcut Amivantamab Reduced Infusion Reactions 5-Fold

PALOMA-3: 5-Min Subcut Amivantamab Reduced Infusion Reactions 5-Fold
PR NEWSWIRE
31 May 2024
Share Share
RYBREVANT® Plus Lazertinib Shows Longer PFS Vs Osimertinib In EGFR+ NSCLC

RYBREVANT® Plus Lazertinib Shows Longer PFS Vs Osimertinib In EGFR+ NSCLC
PR NEWSWIRE
31 May 2024
Share Share
J&J Submits sBLA and NDA to U.S. FDA Seeking Approval of RYBREVANT

J&J Submits sBLA and NDA to U.S. FDA Seeking Approval of RYBREVANT
PR NEWSWIRE
21 Dec 2023
Share Share
J&J details Tagrisso-topping data for Rybrevant, Leclaza combo

J&J details Tagrisso-topping data for Rybrevant, Leclaza combo
PR NEWSWIRE
24 Oct 2023
Share Share
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
PR NEWSWIRE
23 Oct 2023
Share Share
J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win
Lei Lei Wu ENDPTS
29 Sep 2023
Share Share
Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC

Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC
PR NEWSWIRE
11 Sep 2023
Share Share